{
  "outcomes_metadata": {
    "timestamp": "2025-10-02T14:29:43.457827",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 44,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "overall survival (time from randomisation to death from any cause)",
        "overall survival (time from randomization to death from any cause)",
        "progression-free survival (PFS)",
        "progression-free survival (blinded, independent central review)",
        "progression-free survival (investigator-assessed)",
        "progression-free survival (independent review committee, blinded; RECIST 1.1)",
        "event-free survival",
        "eventless survival",
        "prolonged survival",
        "progression after next line of therapy (PFS2)",
        "quality-adjusted life years (QALYs)"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (independent review committee, blinded; RECIST 1.1)",
        "overall response rate (ORR)",
        "response rate",
        "disease control rate",
        "disease control rate (proportion of patients with complete, partial, or stable disease for at least 5 weeks)",
        "duration of response (DoR)",
        "duration of response (RECIST 1.1)",
        "time to response (time from treatment initiation to first complete or partial response)",
        "treatment duration",
        "duration of treatment"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "time to next treatment (TTNT)",
        "time to next treatment"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse events (CTCAE v5.0)",
        "adverse events (CTCAE v4.03)",
        "side effects",
        "serious adverse events",
        "serious adverse events (Grade 3-4)",
        "serious undesirable effects",
        "mortality-related toxicity",
        "serious side effects on the skin",
        "diarrhoea",
        "alanine aminotransferase increase",
        "aspartate aminotransferase increase",
        "neutropenia",
        "febrile neutropenia",
        "fatigue"
      ],
      "serious_events": [
        "serious adverse events",
        "serious adverse events (Grade 3-4)",
        "serious undesirable effects",
        "serious side effects on the skin",
        "mortality-related toxicity"
      ],
      "discontinuations": [
        "dropout rate"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-LC13",
        "BPI-SF",
        "FACT-G GP5",
        "PGI-C",
        "EQ-5D-5L",
        "visual analogue scale"
      ],
      "functional_status": [
        "Karnofsky performance status",
        "ECOG performance status",
        "physical functioning"
      ],
      "symptom_measures": [
        "symptomatology",
        "symptom control",
        "health status",
        "overall health status",
        "health-related quality of life",
        "health-related quality of life (measured by time to death)",
        "quality of life",
        "preservation of quality of life"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (cost per QALY achieved)"
      ],
      "utilities": [
        "utility decrement per cycle of treatment",
        "treatment-related disutility for intravenous administration"
      ],
      "resource_utilization": []
    },
    "other": {
      "exploratory_endpoints": [],
      "biomarkers": []
    }
  }
}